Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile.

Acute myeloid leukemia Clonal disorders Myelodysplastic syndromes

Journal

Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 08 05 2023
accepted: 25 07 2023
pubmed: 3 8 2023
medline: 3 8 2023
entrez: 3 8 2023
Statut: ppublish

Résumé

Diagnosis and prognostic stratification of myelodysplastic syndromes (MDS) have been complemented by new techniques, including flow cytometry and NGS. To analyze the relationship between molecular and cytofluorimetric data, we enrolled in this retrospective study, 145 patients, including 106 diagnosed with MDS and 39 controls. At disease onset, immunophenotypic (IF), cytogenetic tests, and cytomorphological (CM) examination on bone marrow were carried out in all patients, while NGS was performed in 58 cases. Ogata score presented a specificity of 100% and a sensitivity of 59%. The detection of at least two phenotypic aberrancies in Ogata negative patients increased the sensitivity to 83% and specificity to 87%. Correlations were identified between IF aberrancies and mutations, including positive Ogata>2 and mutations in SRSF2 (p=0.035), CD15 and U2AF1 (0.032), CD56 and DNMT3A (p=0.042), and CD38 and TP53 (p=0.026). In multivariate analysis, U2AF1 mutations, associated with del(20q) and/or abnormalities of chromosome 7 (group 4 as defined by the EuroMDS score), significantly correlated with an inferior overall survival (p=0.019). These parameters and Ogata score>2 also showed a significant correlation with inferior event-free survival (p=0.023 and p=0.041, respectively). Both CM and FC features correlated with prognosis and mutational patterns. In an integrated MDS work-up, these tools may guide indications for mutational screening for optimal risk stratification.

Identifiants

pubmed: 37535147
doi: 10.1007/s00277-023-05384-2
pii: 10.1007/s00277-023-05384-2
pmc: PMC10567902
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3015-3023

Subventions

Organisme : AIRC 5X1000 MYNERVA
ID : 21267
Organisme : PNRR
ID : PE00000019
Organisme : Celgene
ID : CL-MDS-PI-13673

Informations de copyright

© 2023. The Author(s).

Références

Ann Lab Med. 2017 Sep;37(5):450-453
pubmed: 28643497
Haematologica. 2017 Feb;102(2):320-326
pubmed: 27658438
Blood. 2008 Feb 1;111(3):1067-77
pubmed: 17971483
Blood Adv. 2021 Feb 23;5(4):1017-1028
pubmed: 33591325
Bone Marrow Transplant. 2019 Aug;54(8):1281-1286
pubmed: 30655603
Cancer. 2010 Oct 1;116(19):4549-63
pubmed: 20572043
Leuk Res. 2004 Nov;28(11):1171-5
pubmed: 15380341
Leukemia. 2013 Oct;27(10):1981-7
pubmed: 23765225
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leuk Lymphoma. 2020 Jun;61(6):1455-1464
pubmed: 32026740
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
pubmed: 24030381
Am J Clin Pathol. 2020 Mar 9;153(4):554-565
pubmed: 32011681
PLoS One. 2020 Jan 24;15(1):e0227986
pubmed: 31978184
Leukemia. 2015 Jan;29(1):66-75
pubmed: 24935723
Haematologica. 2021 Mar 01;106(3):701-707
pubmed: 32241844
Cytometry B Clin Cytom. 2020 May;98(3):250-258
pubmed: 31479199
Haematologica. 2015 Apr;100(4):472-8
pubmed: 25637056
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
Leuk Res. 2022 Feb;113:106789
pubmed: 35101793
Pediatr Blood Cancer. 2009 Mar;52(3):357-63
pubmed: 19061215
Cytometry B Clin Cytom. 2014 May;86(3):207-15
pubmed: 24474614
Exp Hematol Oncol. 2022 Oct 17;11(1):73
pubmed: 36253799
Cytometry B Clin Cytom. 2023 Jan;104(1):15-26
pubmed: 34894176
Leukemia. 2014 Sep;28(9):1793-8
pubmed: 24919805
Cancer Med. 2021 Jun;10(12):3839-3847
pubmed: 34042280
Haematologica. 2012 Aug;97(8):1209-17
pubmed: 22315489
Int J Lab Hematol. 2017 Dec;39(6):577-584
pubmed: 28625017
Leuk Res. 2009 Feb;33(2):326-31
pubmed: 18718658
J Clin Oncol. 2021 Apr 10;39(11):1223-1233
pubmed: 33539200
Leuk Res. 2006 Aug;30(8):957-63
pubmed: 16417922
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Br J Haematol. 2020 Mar;188(5):605-622
pubmed: 31621063
BMC Genomics. 2021 Dec 16;22(1):903
pubmed: 34915860
Br J Haematol. 1987 Aug;66(4):445-50
pubmed: 3478074
Leukemia. 1992 Jun;6(6):520-5
pubmed: 1318461
Blood. 2002 Dec 1;100(12):3887-96
pubmed: 12393641
Leukemia. 2014 Feb;28(2):241-7
pubmed: 24220272
Leuk Res. 2008 Jan;32(1):185-6
pubmed: 17383724
Clin Exp Med. 2020 Aug;20(3):361-371
pubmed: 32613269
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
Haematologica. 2009 Aug;94(8):1066-74
pubmed: 19546439

Auteurs

Luca Guarnera (L)

Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Emiliano Fabiani (E)

Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.

Cristina Attrotto (C)

Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Hajro Hajrullaj (H)

Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Antonio Cristiano (A)

Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Roberto Latagliata (R)

Haematology Division, Ospedale Belcolle, Viterbo, Italy.

Susanna Fenu (S)

Haematology Department, San Giovanni-Addolorata Hospital, Rome, Italy.

Francesco Buccisano (F)

Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Maria Irno-Consalvo (M)

Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Consuelo Conti (C)

Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Maria Teresa Voso (MT)

Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy. voso@med.uniroma2.it.
Neuro-Oncohematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia, Rome, Italy. voso@med.uniroma2.it.

Luca Maurillo (L)

Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Classifications MeSH